Articles by A. Nair - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by A. Nair

A. Nair


A. Nair is a freelance writer based in Mumbai, India.

Articles
Report from India
February 2, 2012

The Asian nation is strategizing to take the lead over its regional competitors in pharmaceutical exports.

Report from India
October 2, 2011

In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.

Report from India
June 2, 2011

India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.

Report from India
February 2, 2011

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Report from India
November 2, 2010

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

Report from India
July 2, 2010

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

Report from India
March 2, 2010

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

In the Field: Report from India
December 2, 2009

Multinational firms and governments around the world are flocking to India for R&D partnerships.

Report From: India
October 2, 2009

Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here